Advertisement

Advertisement

Lung Cancer
Pancreatic Cancer

eNRGy Trial: Zenocutuzumab for NRG1 Gene Fusion–Positive Solid Tumors

Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors, according to results from the registrational phase II eNRGy study published by Schram et al in The New England Journal of Medicine....

Lung Cancer

Mobocertinib vs Platinum-Based Chemotherapy in First-Line Treatment of EGFR Exon 20 Insertion–Positive Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Jänne et al, an interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib—an EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion (ex20ins) mutations—compared with...

Solid Tumors
Issues in Oncology
Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Lung Cancer
Hepatobiliary Cancer

Trends in Cancer Incidence and Mortality in Appalachia

Investigators have found that although fewer patients may be diagnosed with and dying from cancer in Appalachia, cancer incidence and mortality rates remain substantially higher compared with elsewhere in the United States, according to a recent study published by Burus et al in the Journal of the...

Lung Cancer
Genomics/Genetics
Issues in Oncology

Predicting Response to KRAS G12C Inhibitors in NSCLC

Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...

Lung Cancer

Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC

As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...

Lung Cancer
Issues in Oncology

Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC

Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual...

Lung Cancer

Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option

In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...

Lung Cancer

Getting a Lung Cancer Diagnosis Was Shocking

For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...

Lung Cancer

Even Low Levels of ctDNA May Be Linked to Recurrence Risk in Early Lung Cancer, Study Finds

Lung cancer is the second most common cancer in the United States, but high recurrence rates persist for patients with early-stage disease. A recent study published by Black et al in Nature Medicine has found that even very low traces of circulating tumor DNA (ctDNA) may be linked to increased...

Issues in Oncology
Lung Cancer

Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity

Lung cancer is the second most common cancer, excluding skin cancer, diagnosed in men and women in the United States. And despite advances in treatment for the disease, which have led to improved survival rates, lung cancer remains the leading cause of cancer mortality in the United States, with...

Lung Cancer
Issues in Oncology
Global Cancer Care

Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality

Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in...

Lung Cancer

Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations

As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan (Dato-DXd) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations whose disease progressed...

Lung Cancer
Issues in Oncology

ORACLE Test May Predict Survival in Early Stages of Lung Cancer

The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors, according to a recent study published by Biswas et al in Nature Cancer. The findings could help physicians make more informed treatment decisions...

Lung Cancer

Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced...

Lung Cancer

FDA Approves Ensartinib for ALK- Positive Locally Advanced or Metastatic NSCLC

On December 18, 2024, the U.S. Food and Drug Administration (FDA) approved the anaplastic lymphoma kinase (ALK) inhibitor ensartinib (Ensacove) for adults with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. For full...

lung cancer

Second-Line Treatment of KRAS-Mutant Metastatic NSCLC

This is Part 2 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the second-line treatment of a patient with KRAS-mutant metastatic non–small cell lung cancer (NSCLC). The patient is a 67-year-old woman who is diagnosed with lung adenocarcinoma with oligoprogressive disease, PD-L1 expression of 10%, and KRAS G12C, STK11, and KEAP1 mutations. She receives initial therapy with chemotherapy and dual checkpoint inhibition but shows evidence of disease progression after 8 cycles of therapy.   In the conversation that follows, the faculty discuss the local treatment options for oligoprogressive KRAS G12C–mutant lung cancer after disease progression, how the currently approved KRAS G12C inhibitors compare with docetaxel, and treatment considerations when using KRAS inhibitors.

lung cancer

First-Line Treatment of KRAS-Mutant NSCLC

This is Part 1 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the first-line treatment of a patient with KRAS-mutant non–small cell lung cancer (NSCLC). The patient is a 58-year-old woman who presents with bilateral lung masses and is found to have diffusely metastatic lung adenocarcinoma with KRAS G12D, TP53, and STK11 mutations, and a PD-L1 expression of 30%.   In the conversation that follows, the faculty discuss the importance of upfront testing for all genomic alterations, whether all KRAS mutations are actionable, and the role of tumor histology and PD-L1 status in determining appropriate first-line therapy.

Lung Cancer

Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...

Immunotherapy
Lung Cancer

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...

Lung Cancer
Pancreatic Cancer

FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with the following types of lung and pancreatic cancers: advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)...

Lung Cancer

AI and the Future of Lung Cancer Screening: Still Room for Improvement

“Artificial intelligence [AI] will be used in all aspects of [lung cancer] screening…, and it continues to get better,” commented topic overview speaker David F. Yankelevitz, MD, Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York, at the Quantitative Imaging Workshop...

Lung Cancer

Study Evaluating Lung Cancer Screening Program Receives Margulis Award for Scientific Excellence

The 2024 Alexander R. Margulis Award for Scientific Excellence honored the authors of a 20-year follow-up study on the International Early Lung Cancer Action Program (I-ELCAP). The Margulis Award was presented recently during the 2024 Radiological Society of North America (RSNA) Scientific Assembly ...

Solid Tumors
Issues in Oncology
Lung Cancer

Regional, Racial, Economic Disparities in Air Pollution–Related Cancer Risk May Be Improving but Still Persist

Investigators report they have uncovered patterns in the risk of cancer associated with lifetime exposure to air pollution and how this risk may have changed over time, in a recent study published by Hurbain et al in Environmental Science & Technology. The findings could build on the scientific ...

Lung Cancer

Toripalimab Plus Chemotherapy in First-Line Therapy for Extensive-Stage Small Cell Lung Cancer

In a Chinese phase III trial (EXTENTORCH) reported in JAMA Oncology, Cheng et al reported that the addition of the immunoglobulin G4 PD-1–blocking antibody toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin (EP) improved progression-free survival among patients with ...

Lung Cancer
Cardio-oncology
Issues in Oncology

Lung Cancer CT Screening May Help to Detect Coronary Artery Disease

Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal. Background Lung cancer is currently one...

Lung Cancer
Issues in Oncology

Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC

Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for comparing the pharmacokinetic properties of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and their major metabolites in mouse...

Lung Cancer

Prognostic Factors in Limited-Stage SCLC Treated With Escalated Radiotherapy Doses

In a study reported in JAMA Network Open, Farris et al identified prognostic factors in patients with limited-stage small cell lung cancer (SCLC) receiving radiotherapy at two dose schedules in the CALGB 30610–RTOG 0538 trial. Study Details In the trial, 638 patients were randomly assigned between...

lung cancer

Patient With Metastatic NSCLC and Brain Metastasis

This is Part 3 of First-Line Immunotherapy for Metastatic NSCLC: Special Populations and Unmet Needs, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Roy Herbst, Charu Aggarwal, and Karen Reckamp discuss the first-line management of a patient with metastatic non–small cell lung cancer (NSCLC) and brain metastasis. The patient is a 64-year-old male who presents with left neck adenopathy. He is a former smoker with a 15 pack-year smoking history but quit 10 years ago. Positron-emission tomography shows an FDG-avid large left upper lobe mass with left axillary, left cervical, and left mediastinal lymph nodes, as well as a left lower lobe satellite lesion. Fine-needle aspiration of the left cervical lymph node is positive for NSCLC, adenocarcinoma subtype. PD-L1 TPS is 1%. Next-generation sequencing reveals no actionable mutations. During staging workup and molecular profiling, he develops weakness on his left side, and brain MRI reveals a 1.6-cm right frontal lobe mass with surrounding edema.   In the conversation that follows, the faculty discuss whether surgical resection would be appropriate for this patient with brain metastasis, the optimal systemic treatment regimen of choice following local treatment of the brain lesion, and whether restaging is necessary.

lung cancer

Patient With PD-L1–Negative Metastatic NSCLC

This is Part 2 of First-Line Immunotherapy for Metastatic NSCLC: Special Populations and Unmet Needs, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Roy Herbst, Charu Aggarwal, and Karen Reckamp discuss the first-line management of a patient with PD-L1–negative metastatic non–small cell lung cancer (NSCLC). The patient is a 57-year-old Asian American female who presents with stage IV lung adenocarcinoma with a left lower lobe mass, bulky hilar and mediastinal metastases, and multiple bone lesions, including in the ribs and pelvis. She is a former smoker with a 15 pack-year smoking history but quit 20 years ago. Her performance status is 1. Fine-needle aspiration of the left lower primary is positive for lung adenocarcinoma; her PD-L1 expression is 0%, and next-generation sequencing reveals no actionable markers.   In the conversation that follows, the faculty discuss potential treatment options in the first-line setting, whether a poor performance status or other risk factors would change a decision to use dual checkpoint blockade, and the importance of obtaining an accurate molecular profile, particularly in patients with lung cancer who have a history of smoking.

lung cancer

Patient With Metastatic Squamous NSCLC

This is Part 1 of First-Line Immunotherapy for Metastatic NSCLC: Special Populations and Unmet Needs, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Roy Herbst, Charu Aggarwal, and Karen Reckamp discuss the first-line management of a patient with metastatic non–small cell lung cancer (NSCLC) with squamous cell histology. The patient is a 63-year-old man with a prior 30 pack-year smoking history who presents with cough and shortness of breath. A CT scan reveals a left upper lobe primary mass, mediastinal and hilar adenopathy, and bilateral lung and bone metastases. Fine-needle biopsy reveals TTF1-negative NSCLC with squamous cell histology. Brain MRI is negative for metastatic disease, and PD-L1 expression is 10%.   In the conversation that follows, the faculty discuss next steps for this patient, whether tumor profiling is necessary in patients with squamous histology, considerations for the use of CTLA-4 inhibitors, and what immune-related adverse events clinicians should be aware of in patients with lung cancer.

Lung Cancer

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...

Breast Cancer
Lung Cancer
Hepatobiliary Cancer
Gastroesophageal Cancer
Prostate Cancer
Skin Cancer
Immunotherapy

Highlights From the ESMO Congress 2024

The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...

Lung Cancer

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

Lung Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...

Lung Cancer

4-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

Neoadjuvant chemotherapy with vs without the PD-1 inhibitor nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the...

Solid Tumors
Thyroid Cancer
Lung Cancer
Gynecologic Cancers
Colorectal Cancer

Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?

Just 50% of patients with early-onset cancers may report discussing fertility preservation options with their physicians prior to receiving oncology treatments, according to a recent study published by Keller et al in JAMA Network Open. Background “From an early-onset cancer diagnosis through to...

Lung Cancer

Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study.1 The findings were presented at the International Association for...

Lung Cancer

TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC

The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...

Lung Cancer

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

Lung Cancer

New Hope for Patients With HER2-Mutant NSCLC: Durable Responses to Two Novel Targeted Therapies

Two novel oral HER2 tyrosine kinase inhibitors have demonstrated promising efficacy in patients with HER2-mutant non–small cell lung cancer (NSCLC), potentially transforming the treatment landscape for this challenging subset of lung cancer cases. According to data presented at the International...

Lung Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...

Lung Cancer

Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC

The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...

Lung Cancer

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody (targeting both PD-1 and the vascular endothelial growth factor [VEGF]) ivonescimab was compared with the PD-1 inhibitor pembrolizumab as first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab ...

Lung Cancer

‘Encouraging’ Pathologic Responses Achieved With Novel Combination Regimen in Early-Stage NSCLC

In the multiarm phase II NeoCOAST-2 trial, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus the monoclonal antibody durvalumab and single-agent platinum chemotherapy led to promising rates of pathologic complete and major pathologic responses in patients with early-stage non–small...

Lung Cancer

Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC

An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...

Lung Cancer

Highlights From the 2024 World Conference on Lung Cancer

At the 2024 World Conference on Lung Cancer (WCLC), more than 7,000 clinicians and scientists gathered in San Diego in celebration of the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). In this supplement to The ASCO Post, we review impactful abstracts from...

Lung Cancer
Issues in Oncology

Detecting Evidence of Lung Cancer in Exhaled Breath

Researchers may have developed ultrasensitive, nanoscale sensors that distinguished a key change in the chemistry of the breath of patients with lung cancer, according to a recent study published by Cheng et al in ACS Sensors. Background Individuals breathe out many gases, such as water vapor and...

Lung Cancer

SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer

A phase II study by Riess et al investigating the IO102-IO103 vaccine plus pembrolizumab as first-line treatment in patients with non–small cell lung cancer (NSCLC) showed “promising” overall response rates and 6-month progression-free survival, with an acceptable safety profile. The study...

Lung Cancer

Tarlatamab-dlle for Previously Treated Extensive-Stage SCLC

On May 16, 2024, tarlatamab-dlle (Imdelltra) was granted accelerated approval for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager. Supporting Efficacy...

Lung Cancer
Issues in Oncology

$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities

Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb...

Advertisement

Advertisement

Advertisement